SG11201909584QA - Triterpene saponin analogues - Google Patents

Triterpene saponin analogues

Info

Publication number
SG11201909584QA
SG11201909584QA SG11201909584QA SG11201909584QA SG 11201909584Q A SG11201909584Q A SG 11201909584QA SG 11201909584Q A SG11201909584Q A SG 11201909584QA SG 11201909584Q A SG11201909584Q A SG 11201909584QA
Authority
SG
Singapore
Prior art keywords
international
new york
street
pct
strain
Prior art date
Application number
Inventor
Philip Livingston
Govind Ragupathi
Jeffrey Gardner
J Martin
Original Assignee
Adjuvance Technologies Inc
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adjuvance Technologies Inc, Memorial Sloan Kettering Cancer Center filed Critical Adjuvance Technologies Inc
Publication of SG11201909584QA publication Critical patent/SG11201909584QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

1 kr) 71' O O N 00 O 1-1 N C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT mu °mons ono o Holonillioomunom oimIE (10) International Publication Number WO 2018/200645 Al (51) International Patent Classification: A61K 31/704 (2006.01) C07H 15/256 (2006.01) A61P 37/04 (2006.01) (21) International Application Number: PCT/US2018/029314 (22) International Filing Date: 25 April 2018 (25.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/489,556 25 April 2017 (25.04.2017) US (71) Applicant: ADJUVANCE TECHNOLOGIES, INC. [US/US]; 16 West 22nd Street, 6th Floor, New York, NY 10010 (US). (72) Inventors: LIVINGSTON, Philip; 156 East 79th Street, Apt. 6C, New York, NY 10075 (US). RAGUPATHI, Govind; 303 East 60th Street, #35G, New York, NY 10022 (US). GARDNER, Jeffrey; 116 W22nd St, Apt 1, New York, NY 10011 (US). MARTIN, J, Tyler; 5200 Quarry Ledge Road, Roca, NE 68430 (US). (74) Agent: STRAIN, Paul D.; Strain & Strain PLLC, 1455 Pennsylvania Ave, N.W., Suite 400, Washington, DC 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: TRITERPENE SAPONIN ANALOGUES FIG. I (57) : The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases. [Continued on next page] WO 2018/200645 Al MIDEDIMOMMIDIIMEIEHNOMMINIMMOVOIMIE Published: — with international search report (Art. 21(3))
SG11201909584Q 2017-04-25 2018-04-25 Triterpene saponin analogues SG11201909584QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762489556P 2017-04-25 2017-04-25
PCT/US2018/029314 WO2018200645A1 (en) 2017-04-25 2018-04-25 Triterpene saponin analogues

Publications (1)

Publication Number Publication Date
SG11201909584QA true SG11201909584QA (en) 2019-11-28

Family

ID=63918682

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202108075YA SG10202108075YA (en) 2017-04-25 2018-04-25 Triterpene saponin analogues
SG11201909584Q SG11201909584QA (en) 2017-04-25 2018-04-25 Triterpene saponin analogues

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202108075YA SG10202108075YA (en) 2017-04-25 2018-04-25 Triterpene saponin analogues

Country Status (11)

Country Link
US (1) US20210283248A1 (en)
EP (1) EP3618836A4 (en)
JP (2) JP2020517679A (en)
KR (1) KR20190137827A (en)
CN (1) CN110582282A (en)
AU (1) AU2018258070A1 (en)
CA (1) CA3061205A1 (en)
CL (1) CL2019003064A1 (en)
IL (2) IL292991A (en)
SG (2) SG10202108075YA (en)
WO (1) WO2018200645A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019079160A1 (en) * 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. Triterpene saponin analogues
GB2592769B (en) * 2020-03-01 2022-05-04 Valneva Austria Gmbh CpG-Adjuvanted SARS-CoV-2 virus vaccine
WO2023056089A1 (en) 2021-10-03 2023-04-06 Eisai R&D Management Co., Ltd. Immunological adjuvant formulations comprising tlr4 agonist e6020
EP4190359A1 (en) 2021-12-03 2023-06-07 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Saponin-based adjuvants and vaccines
WO2023139145A1 (en) 2022-01-19 2023-07-27 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Saponin-based adjuvants and vaccines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US8029795B2 (en) * 1999-12-30 2011-10-04 Gwathmey, Inc. Targeted iron chelator delivery system
GB0401239D0 (en) * 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
CN102940878A (en) * 2006-10-06 2013-02-27 Scil技术股份有限公司 Spinal nucleus pulposus implant
EP2234637A2 (en) * 2007-12-21 2010-10-06 GlaxoSmithKline Biologicals S.A. Vaccines for malaria
EP2280987B1 (en) * 2008-04-08 2018-05-23 Sloan-Kettering Institute for Cancer Research Triterpene saponins, methods of synthesis, and uses thereof
CA2720961A1 (en) * 2008-04-16 2009-10-22 William Ripley Ballou, Jr. Streptococcus pneumonia vaccine
AU2011258165B2 (en) * 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US20130309273A1 (en) * 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
AU2016349693B2 (en) * 2015-11-06 2022-08-11 Adjuvance Technologies, Inc. Triterpene saponin analogues
JP2020516657A (en) * 2017-04-13 2020-06-11 アジュバンス・テクノロジーズ・インコーポレーテッド Triterpene saponin synthesis, combination of intermediates and adjuvants

Also Published As

Publication number Publication date
EP3618836A4 (en) 2021-01-13
WO2018200645A1 (en) 2018-11-01
IL292991A (en) 2022-07-01
EP3618836A1 (en) 2020-03-11
US20210283248A1 (en) 2021-09-16
CA3061205A1 (en) 2018-11-01
CN110582282A (en) 2019-12-17
JP2022191284A (en) 2022-12-27
AU2018258070A1 (en) 2019-10-24
JP2020517679A (en) 2020-06-18
CL2019003064A1 (en) 2020-03-13
KR20190137827A (en) 2019-12-11
SG10202108075YA (en) 2021-09-29
IL270182B (en) 2022-06-01

Similar Documents

Publication Publication Date Title
SG11201909584QA (en) Triterpene saponin analogues
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201808990QA (en) Compositions for topical application of compounds
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201811432WA (en) Rna for cancer therapy
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201909311TA (en) Triterpene saponin synthesis, intermediates and adjuvant combinations
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201907023UA (en) Method of reducing neutropenia
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201806845VA (en) Moisturizing compositions and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201811559WA (en) Cancer treatment combinations